Shuttle Pharma Announces Q2 2025 Update: Phase 2 Trial Progress, Financial Strength, and Leadership Enhancements

Shuttle Pharmaceuticals (SHPH) has reported a 63% enrollment rate in its Phase 2 trial for Ropidoxuridine, a treatment for glioblastoma, with 72% of participants completing all seven treatment cycles. The company has $4.8 million in cash, bolstered by a $4.25 million private placement, and has strengthened its leadership with George Scorsis as Chairman and Christopher Cooper joining the Board. The Phase 2 trial is expected to complete enrollment by late 2025, with data readouts anticipated in 2026.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), has reported significant progress in its Phase 2 clinical trial for Ropidoxuridine, a treatment for glioblastoma. The company announced that 63% enrollment has been achieved in the trial, with 72% of enrolled patients completing all seven treatment cycles. The drug has been reported as well-tolerated by treatment sites [1].

The company ended the second quarter of 2025 with $4.8 million in cash, bolstered by a $4.25 million private placement in June 2025 [2]. This financial stability will support the continuation and potential expansion of their clinical trials. Additionally, Shuttle Pharmaceuticals has strengthened its leadership by appointing George Scorsis as Chairman of the Board and Christopher Cooper to the Board of Directors [3].

The Phase 2 trial for Ropidoxuridine is scheduled to complete enrollment by late 2025, with data readouts anticipated in 2026. The trial aims to optimize radiation therapy for glioblastoma, a deadly malignancy of the brain with no known cure. The company has received Orphan Drug Designation from the FDA, which could provide marketing exclusivity upon approval, significantly enhancing its commercial potential in a growing market [1].

Shuttle Pharmaceuticals was founded in 2012 by faculty members of the Georgetown University Medical Center. Its mission is to improve the lives of cancer patients by developing therapies that maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment [1].

References:
[1] https://www.stocktitan.net/news/SHPH/shuttle-pharma-provides-second-quarter-2025-corporate-7vzt9zao05yi.html
[2] https://www.gurufocus.com/news/3062678/shuttle-pharma-provides-second-quarter-2025-corporate-update-shph-stock-news
[3] https://www.morningstar.com/news/globe-newswire/9512701/shuttle-pharma-provides-second-quarter-2025-corporate-update